FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312212110> ?p ?o ?g. }

• W4312212110 endingPage "102185" @default.
• W4312212110 startingPage "102185" @default.
• W4312212110 abstract "Allergic asthma is a heterogeneous disease involving a variety of inflammatory cells. Immune imbalance or changes in the immune microenvironment are the essential causes that promote inflammation in allergic asthma. Tetraspanin CD81 can be used as a platform for receptor clustering and signal transmission owing to its special transmembrane structure and is known to participate in the physiological processes of cell proliferation, differentiation, adhesion, and migration. Previous studies have shown that CD81-targeting peptidomimetics exhibit anti-allergic lung inflammation. However, due to the low metabolic stability of peptide drugs, their druggability is limited. Here, we aimed to generate a metabolically stable anti-CD81 peptide, evaluate its anti-inflammatory action and establish its mechanism of action. Based on previous reports, we applied retro-inverse peptide modification to obtain a new compound, PD00 (NH2-D-Gly-D-Ser-D-Thr-D-Tyr-D-Thr-D-Gln-D-Gly-COOH), with high metabolic stability. Enhanced ultraperformance liquid chromatography-tandem mass spectrometry was used to investigate the in vitro and in vivo metabolic stabilities of PD00. The affinities of PD00 and CD81 were studied using molecular docking and surface plasmon resonance techniques. An ovalbumin (OVA)-induced asthma model was used to evaluate the effects of PD00 in vivo. Mice were treated with different concentrations of PD00 (175 and 350 μg/kg) for 10 days. Airway hyperresponsiveness (AHR) to acetyl-β-methacholine (Mch), inflammatory cell counts in the bronchoalveolar lavage fluid, and serum OVA-specific IgE levels were detected in the mice at the end of the experiment. Lung tissues were collected for haematoxylin and eosin staining, untargeted metabolomic analysis, and single-cell transcriptome sequencing. PD00 has a high affinity for CD81; therefore, administration of PD00 markedly ameliorated AHR and airway inflammation in mice after OVA sensitisation and exposure. Serum OVA-specific IgE levels decreased considerably. In addition, PD00 treatment increased glycerophospholipid and purine metabolism in immune cells. Collectively, PD00 may regulate the glycerophospholipid and purine metabolism pathways to ameliorate the pathophysiological features of asthma. These findings suggest that PD00 is a potential compound for the treatment of asthma." @default.
• W4312212110 created "2023-01-04" @default.
• W4312212110 creator A5018892762 @default.
• W4312212110 creator A5022476435 @default.
• W4312212110 creator A5039084645 @default.
• W4312212110 creator A5045019377 @default.
• W4312212110 creator A5063481044 @default.
• W4312212110 creator A5064564309 @default.
• W4312212110 creator A5078315542 @default.
• W4312212110 creator A5078355510 @default.
• W4312212110 creator A5080513377 @default.
• W4312212110 creator A5082538019 @default.
• W4312212110 creator A5085267077 @default.
• W4312212110 creator A5090270861 @default.
• W4312212110 date "2023-02-01" @default.
• W4312212110 modified "2023-09-30" @default.
• W4312212110 title "A retro-inverso modified peptide alleviated ovalbumin-induced asthma model by affecting glycerophospholipid and purine metabolism of immune cells" @default.
• W4312212110 cites W1679882910 @default.
• W4312212110 cites W2021393435 @default.
• W4312212110 cites W2039137107 @default.
• W4312212110 cites W2083120327 @default.
• W4312212110 cites W2102212449 @default.
• W4312212110 cites W2110667006 @default.
• W4312212110 cites W2123093878 @default.
• W4312212110 cites W2123245589 @default.
• W4312212110 cites W2126463975 @default.
• W4312212110 cites W2138237669 @default.
• W4312212110 cites W2144376155 @default.
• W4312212110 cites W2146649884 @default.
• W4312212110 cites W2157650875 @default.
• W4312212110 cites W2157954742 @default.
• W4312212110 cites W2159315731 @default.
• W4312212110 cites W2167499172 @default.
• W4312212110 cites W2171152683 @default.
• W4312212110 cites W2416927689 @default.
• W4312212110 cites W2753897603 @default.
• W4312212110 cites W2794480084 @default.
• W4312212110 cites W2907514116 @default.
• W4312212110 cites W2948988173 @default.
• W4312212110 cites W2953151710 @default.
• W4312212110 cites W2980678844 @default.
• W4312212110 cites W2999832851 @default.
• W4312212110 cites W3011793807 @default.
• W4312212110 cites W3020409391 @default.
• W4312212110 cites W3025164711 @default.
• W4312212110 cites W3040124259 @default.
• W4312212110 cites W3083060968 @default.
• W4312212110 cites W3120960768 @default.
• W4312212110 cites W3129452222 @default.
• W4312212110 cites W3135750143 @default.
• W4312212110 cites W3189436433 @default.
• W4312212110 cites W3193747748 @default.
• W4312212110 cites W4200287764 @default.
• W4312212110 cites W4248037309 @default.
• W4312212110 doi "https://doi.org/10.1016/j.pupt.2022.102185" @default.
• W4312212110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36563740" @default.
• W4312212110 hasPublicationYear "2023" @default.
• W4312212110 type Work @default.
• W4312212110 citedByCount "1" @default.
• W4312212110 countsByYear W43122121102023 @default.
• W4312212110 crossrefType "journal-article" @default.
• W4312212110 hasAuthorship W4312212110A5018892762 @default.
• W4312212110 hasAuthorship W4312212110A5022476435 @default.
• W4312212110 hasAuthorship W4312212110A5039084645 @default.
• W4312212110 hasAuthorship W4312212110A5045019377 @default.
• W4312212110 hasAuthorship W4312212110A5063481044 @default.
• W4312212110 hasAuthorship W4312212110A5064564309 @default.
• W4312212110 hasAuthorship W4312212110A5078315542 @default.
• W4312212110 hasAuthorship W4312212110A5078355510 @default.
• W4312212110 hasAuthorship W4312212110A5080513377 @default.
• W4312212110 hasAuthorship W4312212110A5082538019 @default.
• W4312212110 hasAuthorship W4312212110A5085267077 @default.
• W4312212110 hasAuthorship W4312212110A5090270861 @default.
• W4312212110 hasBestOaLocation W43122121101 @default.
• W4312212110 hasConcept C141105273 @default.
• W4312212110 hasConcept C150903083 @default.
• W4312212110 hasConcept C159654299 @default.
• W4312212110 hasConcept C185592680 @default.
• W4312212110 hasConcept C203014093 @default.
• W4312212110 hasConcept C207001950 @default.
• W4312212110 hasConcept C2776914184 @default.
• W4312212110 hasConcept C2776946954 @default.
• W4312212110 hasConcept C71924100 @default.
• W4312212110 hasConcept C86803240 @default.
• W4312212110 hasConcept C8891405 @default.
• W4312212110 hasConcept C98274493 @default.
• W4312212110 hasConceptScore W4312212110C141105273 @default.
• W4312212110 hasConceptScore W4312212110C150903083 @default.
• W4312212110 hasConceptScore W4312212110C159654299 @default.
• W4312212110 hasConceptScore W4312212110C185592680 @default.
• W4312212110 hasConceptScore W4312212110C203014093 @default.
• W4312212110 hasConceptScore W4312212110C207001950 @default.
• W4312212110 hasConceptScore W4312212110C2776914184 @default.
• W4312212110 hasConceptScore W4312212110C2776946954 @default.
• W4312212110 hasConceptScore W4312212110C71924100 @default.
• W4312212110 hasConceptScore W4312212110C86803240 @default.
• W4312212110 hasConceptScore W4312212110C8891405 @default.
• W4312212110 hasConceptScore W4312212110C98274493 @default.

• next